Raising HDL Cholesterol through Lifestyle and Pharmacological Interventions

Exercise Interventions

Regular aerobic exercise at moderate intensity for at least 30 minutes, 5 times weekly, combined with resistance training, represents the most effective lifestyle intervention for raising HDL cholesterol levels, as recommended by the American College of Cardiology 1, 2
Exercise demonstrates a dose-response relationship with HDL cholesterol—more activity yields greater increases, with prolonged moderate-intensity aerobic exercise at 70-80% heart rate reserve and low-intensity resistance training at 50% of 1 repetition maximum (1RM) being effective 3, 1
For healthy individuals, aiming for at least 30 minutes daily, 5 times weekly, with a target of 1200-1600 kcal per week of exercise expenditure is recommended 3, 1, 2
For those with dyslipidemia, progressing to higher intensity aerobic exercise at 85% maximum heart rate and moderate-to-high intensity resistance training at 75-85% of 1RM can produce greater improvements in the overall lipid profile 3, 1
For limited mobility populations, implementing resistance training progressing from 50% to 75% of 1RM in major muscle groups and circuit training at moderate intensity can be effective 3, 1

Replace saturated fats with monounsaturated fats and polyunsaturated fats rather than increasing carbohydrates, and limit saturated fat to <7% of total daily calories, as recommended by the American Heart Association 1, 2
Completely avoid trans-unsaturated fatty acids (<1% of energy), which actively lower HDL 1, 2
Minimize refined carbohydrates and added sugars, as high-carbohydrate diets reduce HDL levels, and limit beverages and foods with added sugars 1, 2
Include plant stanols/sterols (2g/day) and increase soluble fiber intake (10-25g/day) for overall lipid profile improvement 2
Consume fish, especially oily fish, at least twice weekly for omega-3 fatty acids, and limit dietary cholesterol to <200 mg/day 2

Achieve and maintain a healthy body weight (BMI 18.5-24.9 kg/m²), as excess weight adversely affects HDL levels, and quit smoking immediately, as this single intervention can increase HDL cholesterol by up to 30% 2, 1, 2

Niacin (nicotinic acid) is the most effective drug for raising HDL cholesterol, but can adversely affect blood glucose levels, particularly relevant in diabetic patients, as noted by the American Diabetes Association 4, 1, 2
Fibrates (gemfibrozil, fenofibrate) effectively increase HDL and reduce triglycerides, with gemfibrozil demonstrating a 34% relative reduction in serious coronary events in the VA-HIT trial among patients with low HDL and prior cardiovascular disease 4, 5, 1, 2

Measure lipid levels annually in adults with diabetes or cardiovascular risk factors, and every 2 years for low-risk individuals, with evaluation of lifestyle interventions at regular intervals and consideration of pharmacological therapy at 3-6 months if targets are not achieved 5, 2, 4, 2
Target HDL levels are >40 mg/dL for men and >50 mg/dL for women, due to physiological differences, as recommended by the American College of Cardiology 4, 5

The American College of Cardiology notes that niacin is the most effective medication for raising HDL‑C and has demonstrated coronary heart disease risk reduction in randomized clinical trials both as monotherapy and when combined with statins (high‑quality evidence from multiple RCTs) 6.
A sizable minority of patients experience intolerance to niacin, most commonly flushing, reflecting a moderate‑level safety concern observed in clinical practice 6.

The American College of Cardiology reports that fenofibrate does not interfere with statin metabolism and is unlikely to substantially increase the risk of myopathy when co‑administered with moderate‑dose statins, unlike gemfibrozil (moderate evidence from pharmacokinetic and safety studies) 6.
Combination therapy that includes statins together with nicotinic acid, fenofibrate, or especially gemfibrozil has been associated with an increased risk of myositis; fenofibrate is considered safer than gemfibrozil in this context (moderate evidence from safety analyses) 6.

The American College of Cardiology emphasizes that, although low HDL‑C is a strong predictor of cardiovascular disease, current controlled clinical trial data are insufficient to justify setting specific HDL‑C‑raising targets beyond the conventional thresholds; LDL‑C reduction remains the primary therapeutic objective (low‑level evidence due to lack of definitive outcome trials) 6.